Search for: "Freedom Pharmaceuticals, Inc" Results 81 - 100 of 152
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
23 Aug 2012, 5:53 am by Ed Wallis
 Bayer Pharmaceuticals was formerly known as Berlex, Inc. which was formerly known as Berlex Laboratories. [read post]
3 Jul 2012, 4:26 am by Ed Wallis
 Bayer Pharmaceuticals was formerly known as Berlex, Inc. which was formerly known as Berlex Laboratories. [read post]
6 Jun 2012, 1:24 pm by Ed Wallis
 Bayer Pharmaceuticals was formerly known as Berlex, Inc. which was formerly known as Berlex Laboratories. [read post]
2 May 2012, 4:47 am by Ed Wallis
Manufactured by Bayer Healthcare Pharmaceuticals, Inc., Mirena is an IUD device [intrauterine device] that must be inserted by a trained health care provider and is intended to provide contraceptive protection for up to five years. [read post]
24 Mar 2012, 6:17 am by Ed Wallis
Manufactured by Bayer Healthcare Pharmaceuticals, Inc., Mirena is an IUD device [intrauterine device] that must be inserted by a trained health care provider and is intended to provide contraceptive protection for up to five years. [read post]
9 Jan 2012, 9:26 am
GlaxoSmithKline Inc.Taxation: The minister of National Revenue reassessed GlaxoSmithKline Inc. by increasing its income based on the fact that it overpaid its non-arm’s length supplier for the pharmaceutical ingredient ranitidine. [read post]
19 Dec 2011, 1:38 pm by Antoinette Konski
Prometheus Laboratories, Inc., (reported in our December 7th post) the American Civil Liberties Union Foundation (“ACLU”) and the Public Patent Foundation petitioned the U.S. [read post]
1 Sep 2011, 5:10 pm by INFORRM
IMS Health Inc (23 June 2011) in which the Court voted 6-3 to strike down Vermont’s Prescription Confidentiality Law, which had prohibited the use, sale or disclosure of prescriber histories in pharmaceutical marketing to physicians. [read post]
23 Jun 2011, 12:10 pm by Bexis
IMS Health, Inc., No. 10-779, slip op. [read post]
22 Jun 2011, 7:57 am by Stephen Albainy-Jenei
  As a result, the Generic Pharmaceutical Association believes Section 12 “could reward patent holders that knowingly falsify information in their original patent application with the USPTO or intentionally omit material information. [read post]